Key Points
- CEO William Lewis sold 10,699 shares on Dec. 18 at an average $166.97 for a total of $1,786,412.03, reducing his stake by about 3.4% to 303,911 shares (SEC filing).
- Clinical setback and pipeline reshuffle: a Phase IIb trial in chronic rhinosinusitis failed, prompting termination of that program, a near‑20% after‑hours share plunge, and the company added a new monoclonal‑antibody asset as it reshapes its pipeline.
- Mixed fundamentals with institutional support: Insmed missed EPS estimates (‑$1.75) despite 52% year‑over‑year revenue growth, carries negative margins, but analysts remain mostly positive with an average price target around $205.41 after some downward revisions.
Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the business's stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $166.97, for a total value of $1,786,412.03. Following the sale, the chief executive officer owned 303,911 shares in the company, valued at approximately $50,744,019.67. This represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Insmed Stock Up 5.0%
Shares of INSM stock opened at $174.84 on Friday. Insmed, Inc. has a one year low of $60.40 and a one year high of $212.75. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The stock has a fifty day moving average price of $187.66 and a 200 day moving average price of $143.02. The stock has a market cap of $37.29 billion, a P/E ratio of -28.25 and a beta of 1.01.
Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The business had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. During the same quarter in the prior year, the company posted ($1.27) EPS. The company's quarterly revenue was up 52.4% compared to the same quarter last year. Analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.
Institutional Trading of Insmed
Large investors have recently made changes to their positions in the business. CIBC Private Wealth Group LLC raised its holdings in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 53 shares during the last quarter. ORG Partners LLC grew its holdings in Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 196 shares during the last quarter. Hilltop National Bank acquired a new stake in Insmed in the 2nd quarter valued at about $28,000. Stone House Investment Management LLC bought a new position in shares of Insmed in the third quarter worth about $29,000. Finally, SBI Securities Co. Ltd. raised its stake in shares of Insmed by 404.9% in the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 166 shares during the last quarter.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the company. Cowen set a $241.00 price objective on Insmed in a research note on Thursday. Jefferies Financial Group set a $269.00 price target on Insmed in a research report on Wednesday, December 10th. TD Cowen dropped their price objective on Insmed from $269.00 to $241.00 and set a "buy" rating for the company in a research note on Thursday. Truist Financial initiated coverage on shares of Insmed in a research note on Friday. They issued a "buy" rating and a $202.00 target price on the stock. Finally, Guggenheim lowered their target price on shares of Insmed from $230.00 to $221.00 and set a "buy" rating on the stock in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Insmed currently has an average rating of "Moderate Buy" and an average price target of $205.41.
Check Out Our Latest Report on Insmed
Key Headlines Impacting Insmed
Here are the key news stories impacting Insmed this week:
- Positive Sentiment: Unusual bullish options activity: traders bought a large block of INSM calls (≈6,582 contracts, +78% vs. average), signaling speculative or hedge interest that can support a bounce after the sell‑off.
- Positive Sentiment: Pipeline add — Insmed announced it is adding a new monoclonal‑antibody asset while reshaping its pipeline, which investors may view as a constructive move to offset the terminated sinus program. INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
- Neutral Sentiment: Analysts trimmed targets but mostly stayed constructive — TD Cowen cut its target to $241 and Guggenheim trimmed to $221 while maintaining buy ratings; these lower targets temper upside but keep institutional support. Benzinga analyst note
- Negative Sentiment: Clinical failure and program termination: a Phase IIb trial in chronic rhinosinusitis showed no benefit, leading Insmed to discontinue development of the drug — the principal trigger for the multi‑day share plunge and elevated volatility. High‑flying Insmed stumbles with rhinosinusitis trial failure for Brinsupri
- Negative Sentiment: Market reaction and commentary: coverage noted a near‑20% drop after hours and broad analyst/media focus on the failure; sell‑side and floor commentary (Mizuho/Barron’s) emphasized the stock’s sharp decline. Insmed Stock Plummets 19%
- Negative Sentiment: Analyst EPS downgrade: HC Wainwright cut FY2028 EPS estimates (now $3.15 from $3.42), signaling reduced near‑term earnings expectations tied to program changes and greater uncertainty.
- Negative Sentiment: Insider sale: CEO William Lewis sold 10,699 shares at an average ~$167 on Dec. 18 (SEC filing), reducing his stake ~3.4% — insider selling often raises investor concern when timed near volatile news. SEC Form 4 — William Lewis sale
Insmed Company Profile
(
Get Free Report)
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
